Publication | Open Access
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
15.1K
Citations
7
References
2020
Year
A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
| Year | Citations | |
|---|---|---|
Page 1
Page 1